Silexion Therapeutics Ltd. (SLXN) NASDAQ
0.51
+0.2402(+89.29%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.51
+0.2402(+89.29%)
Currency In USD
Address
The Goldyne Savad Institute of Gene Therapy
Jerusalem, 9112001
Israel
Phone
972 2 674 3430
Website
Sector
Healthcare
Industry
Biotechnology
Employees
11
First IPO Date
August 16, 2024
| Name | Title | Pay | Year Born |
| Ilan Hadar | Chairman & Chief Executive Officer | 347,843 | 1969 |
| Mitchell Shirvan | Chief Scientific & Development Officer | 257,791 | 1954 |
| Mirit Horenshtein Hadar | EVice President of Finance Affairs, Chief Financial Officer & Secretary | 322,799 | 1984 |
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.